Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Pomalyst: multiple myeloma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy

Broader topic: Multiple Myeloma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      after at least 2 prior therapies including lenalidomide and bortezomib and disease prog
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Pomalyst (pomalidomide) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice